<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147676</url>
  </required_header>
  <id_info>
    <org_study_id>7213-2/1</org_study_id>
    <nct_id>NCT04147676</nct_id>
  </id_info>
  <brief_title>Evaluation of Centralised TB Assay Solutions</brief_title>
  <official_title>Multicentre Trial to Assess the Performance of Centralized Assay Solutions for Detection of MTB and Resistance to Rifampin and Isoniazid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis (TB) remains a life-threatening disease partly due to increasing incidence of&#xD;
      multidrug and extensively drug-resistant TB. Diagnostic based on culture and conventional&#xD;
      drug susceptibility testing using media take several weeks leading to prolonged periods of&#xD;
      ineffective therapy and ongoing transmission. Development of rapid molecular diagnostic tests&#xD;
      for the identification of Mycobacterium tuberculosis (MTB) and drug resistance has become a&#xD;
      high priority.&#xD;
&#xD;
      The Xpert® MTB/RIF Assay does not provide information on INH-resistance and the LPA is only&#xD;
      recommended for use in smear-positive samples, complex to perform and requires manual&#xD;
      interpretation. Several novel assays have been recently developed/CE-marked offering high&#xD;
      sample throughput and higher sensitivity for detection of MTB, RIF- and INH-resistance in&#xD;
      centralized laboratories. However, published data on their performance and operational&#xD;
      characteristics is extremely limited.&#xD;
&#xD;
      This is a prospective, multicentre, diagnostic accuracy trial in which the performance of&#xD;
      centralised TB assay solutions will be assessed at the intended setting of use with culture,&#xD;
      phenotypic DST and sequencing as reference standard.&#xD;
&#xD;
      Potential trial participants will be identified at participating TB clinics or hospitals&#xD;
      (enrolment sites). Sputum samples will be collected and transported to the associated TB&#xD;
      reference laboratories (testing sites).&#xD;
&#xD;
      In order for the results of this trial to be generalizable, adults with symptoms compatible&#xD;
      with pulmonary TB undergoing evaluation will be screened for inclusion at geographically&#xD;
      diverse participating centres in high burden TB countries. Additionally, to supplement the&#xD;
      drug-resistant cases to timely achieve accurate performance estimates, well-characterized&#xD;
      frozen sputum samples from the FIND specimen bank will be used.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy for MTB detection</measure>
    <time_frame>four to six months</time_frame>
    <description>clinical sensitivity and specificity by smear-status measured against mycobacterial culture as the reference standard.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for RIF/INH detection</measure>
    <time_frame>four to six months</time_frame>
    <description>clinical point estimates of sensitivity and specificity measured against a composite reference standard of phenotypic DST and targeted sequencing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operational characteristics:</measure>
    <time_frame>four to six months</time_frame>
    <description>description of operator experience with the assays through daily observed usage and user appraisal questionnaires.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Drug-resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>TB suspects</arm_group_label>
    <description>Sputum specimens will be collected from TB suspects enrolled in the study.&#xD;
The specimens will be tested with&#xD;
Roche cobas MTB - for the detection of Mycobacterium tuberculosis complex&#xD;
Roche cobas MTB-RIF/INH - all specimens that are Mycobacterium tuberculosis complex positive will be reflexed to the Roche cobas MTB-RIF/INH test for the detection of resistance to rifampicin and isoniazid&#xD;
Hain FluoroType MTBDR - for the detection of Mycobacterium tuberculosis complex and the detection of resistance to rifampicin and isoniazid</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum specimens M. tuberculosis cultures isolates from patient specimens&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in whom pulmonary TB is suspected. Additionally, well-characterized RIF-resistant&#xD;
        and INH-resistant samples will be used to supplement drug-resistant cases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients are eligible to be included as trial participants only if all of the following&#xD;
        inclusion criteria apply:&#xD;
&#xD;
          -  Aged ≥18 years&#xD;
&#xD;
          -  Clinical suspicion of pulmonary TB including cough ≥2 weeks (or any duration if HIV&#xD;
             positive ) and ≥1 other symptom typical of pulmonary TB listed below:&#xD;
&#xD;
               -  Fever&#xD;
&#xD;
               -  Malaise&#xD;
&#xD;
               -  Recent weight loss&#xD;
&#xD;
               -  Night sweats&#xD;
&#xD;
               -  Contact with active case&#xD;
&#xD;
               -  Haemoptysis&#xD;
&#xD;
               -  Chest pain&#xD;
&#xD;
               -  Loss of appetite&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the trial if any of the following exclusion criteria apply:&#xD;
&#xD;
          -  Unwilling or unable to provide informed consent&#xD;
&#xD;
          -  Unwilling to provide four sputum specimens at enrolment i.e. 2x sputa on day 1 and 2x&#xD;
             sputa on day 2 (up to 1 week from enrolment)&#xD;
&#xD;
          -  Patients with only extra-pulmonary TB signs &amp; symptoms&#xD;
&#xD;
          -  Receipt of any dose of TB treatment within 6 months prior to enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Margaretha de Vos, PhD</last_name>
    <phone>+41 (0) 22 749 29 31</phone>
    <email>margaretha.devos@finddx.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Nabeta, MD</last_name>
    <phone>+41 (0) 22 710 27 87</phone>
    <email>pamela.nabeta@finddx.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Center for Tuberculosis and Lung Diseases</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zaza Avaliani, MD</last_name>
      <phone>(+995)32910251</phone>
    </contact>
    <contact_backup>
      <last_name>Nestani Tukvadze, PhD</last_name>
      <phone>(+995)32910769</phone>
      <email>marikushane@yahoo.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Forschungszentrum Borstel. Leibniz Lungenzentrum (Borstel)</name>
      <address>
        <city>Borstel</city>
        <zip>23845</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Maurer, MD</last_name>
      <phone>+49 4537 188 (2110)</phone>
      <email>fmaurer@fz-borstel.de</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Katrin Witt, PhD</last_name>
      <phone>+49 4537 188 (2050)</phone>
      <email>awitt@fz-borstel.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Indian Council of Medical Research (ICMR) Regional Medical Research Centre</name>
      <address>
        <city>Bhubaneswar</city>
        <zip>751023</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanghamitra Pati, MD</last_name>
      <phone>+91 674 230 1332</phone>
      <email>drsanghamitra12@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dasarathi Das, MD</last_name>
      <phone>+91 943 79 20085</phone>
      <email>drdas60@rediffmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Institute for Research in Tuberculosis</name>
      <address>
        <city>Chennai</city>
        <zip>600031</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Priya Rajendran, MD</last_name>
      <phone>044 -28369660</phone>
      <email>priya.r@nirt.res.in</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Phthisiopneumology &quot;Ch. Draganiuc&quot; (PPI NRL), Moldova</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeriu Crudu, MD</last_name>
      <phone>+373 22 572245</phone>
      <email>valeriu.crudu@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ecaterina Noroc, PhD</last_name>
      <phone>+373 22 794570</phone>
      <email>ecaterina.noroc@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Division of Wits Health Consortium (DMMH)</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Scott, PhD</last_name>
      <phone>+27 11 489 8567</phone>
      <email>lesley.scott@wits.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Anura David, MSc</last_name>
      <phone>+27 11 489 8573</phone>
      <email>anura.david@nhls.ac.za</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Germany</country>
    <country>India</country>
    <country>Moldova, Republic of</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

